ABSTRACT
INTRODUCTION
CNS metastases usually appears late in the progression of metastatic breast cancer and 1 and 2-year survival rates of only 20% and <2%, respectively (1, 2) , Despite the poor prognosis associated with symptomatic CNS metastasis, most patients finally die of systemic disease progression.
In the era of more efficacious chemotherapeutic and tar geted agents for metastatic breast cancer, control of systemic disease has brought the problem that the incidence of CNS metastasis may increase (3, 4) . Until now, all data we have only indicates that over all survival is same between the metastatic breast cancer patients whose brain metastases were diagnosed early without symptoms or lately when they are symptomatic. One of the compel ling questions is if early diagnosis of cranial metastases effects the survival of patients if the brain is the first and only metastatic side after adjuvant treatment or at the initial diagnosis. And second question is 'Is better sur vival possible ıf we treat a patient with early diagnosed brain metastases with current new treatment modalities like targeted therapies and radiosurgery, or surgery with whole brain radiotherapy.
In this study we tried to answer these questions in a very rare group of patients selected from breast cancer data's of two cancer centers.
MATERIAL and METHODS
We have examined about 3600 patients with breast cancer treated in two university hospitals (Meram faculty of medicine hospital and Hacettepe faculty of medicine hospital) between years 2000 and 2012 In those 31 patients with first metastases to brain and no other me tastases after adjuvant treatment or at initial diagnosis of breast cancer were evaluated considering treatment modalities like chemotherapy, targeted therapy, hormonal therapy, either in adjuvant setting or after metastases, surgery with whole brain radiotherapy (WBRT) , radiosurgery or conventional whole brain radiotherapy and mPFS and mOS , ostrogen receptor (ER), progester one receptor (PR) and c-erb2 status were compared in all groups.
Statistical analysis
Data's were analyzed with SPSS 16.0 for Windows Evaluation Version (IBM Corporation, Armonk, NY, USA) İn addition to descriptive analysis like standard devia tion. Median OS were calculated with the KaplanMeier test and the differences between groups were evaluated with the Log Rank test.
RESULTS
31 patients with first metastases to brain and no other metastases after adjuvant treatment or at initial diagnosis of breast cancer were evaluated. 14 patients 45.2% were preperimenouposal and 17 of patients 54.8% were postmenopausal. İn patients 12 38.7% were cerbB2 3+ and 19 of them 61.3% were cerbB2 -and 14 patients %45.25 were ER+ and 17 patients 54.8% were ER . 16 patients 51.6% were found to be PR+ and 15 48.4% were PR. 22 patients had adjuvant taxane, 15 patients had adjuvant hormonal therapy and 6 of them had adjuvant trastuzumab while 3 of them had trastuzumab, 14 had platine and 5 had lapatinib after brain metastases. Ten of these 30 patients were treated with surgery and WBRT and cyberknife or gamma knife on progression. We could not show significant effect of adjuvant tax ane, hormonal therapy and trastuzumab on survival of patients. Also we could not find a significant change on survival of patients, due to trastuzumab and platin administration after brain metastases. But lapatinib ad ministration after metastases showed a significant sur vival advantage. Five patients were administered lapatinib (mOS 41.8 months) and 23 patients weren't (mOS 16 months) p= 0.02 (Table 1) .
Median overall PFS was 8.9 months. Median PFS of group 1 and 2 were 9.1 and 8.6 months (95% confidence in terval). There wasn't significant difference between two groups (p=0.3) (Table1). mOS after the diagnosis of brain metastases were found as 17.7 and 13.6 months respectively but the difference weren't significant (p= 0.2) ( Table 2 ). We couldn't find statistically significant mOS difference between ER and PR receptor positive and negative patients. mOS of ER positive and nega tive patients were 16 and 17,2 months (p= 0.7) and PR positive and negative patients were 10 and 17.7 moths respectively (p= 0.1). mPFS and mOS of cerbB2 positive and negative patients were 8.6 and 6.1 moths (p=0.7) and 17 .3 and 16 months respectively (p=0.9) ( Table 3) . mPFS of group 1 in cerbB2 positive and negative patients were 8.9 and 14.8 months (p= 0.3) and in group 2 pa tients 8.6 and 4.4 months (p= 0.1). Although the surgery with WBRT or cyber-knife or gamma-knife, seems like more effective in cerbB2 negative group and WBRT alone in cerbB2 positive group, the difference were statistically insignificant. mOS of group1 in cerbB2 positive and negative patients were 10.8 and 26.7 months (p= 0.1) and in group 2 17.3 and 10.3 months (p= 0.06). Although results couldn't reach statistically significance, surgery with WBRT and radiosurgery may be more effective in cerbB2 negative group and WBRT alone in cerbB2 positive group which also tented to be statistically signifi cant. mOS for pre and postmenopausal women were 17 and 10 months. The difference was tended to be signifi cant (p= 0.06).
DISCUSSION
CNS metastases are not considered to be a common follow-up parameter in patients with breast carcinoma ıf the patient isn't symptomatic. Several prognostic factors associated with this type of disease recurrence have been identified. It was shown that CNS metastases tend to develop in younger patients who have higher T stage and with more aggressive tumor histology. Many clinical and autopsy data shows that the median age of patients who develop CNS metastases is 5 years younger than that of patients whose disease is metastatic to other sites (5). Pestalozzi et al. (6) were also able to define risk factors for CNS metastases, but they could not show any group at enough risk to justify routine screening for occult CNS metastases. Miller et al. (7) Table 2 . The effect of cerbB2 status on the outcome of treatment modalities were found to be relatively common, but they showed that impact of treating occult CNS disease on survival in patients with progressive systemic metastases was uncertain. But still the compelling question is if there are no systemic metastases except for the brain metastases 'does the treatment modality of cranial metastases effect the survival of patients? ' There are only a few pathfinder studies on this issue. DiStefeno et al in 1979
(1) and patchell et al in 1990 (8) showed that surgery plus RT offers better outcome compared with RT alone in isolated brain metastases. Finding the answer of this question isn't so easy because in study by Pestalozzi et al, they showed in 9524 patients that overall, CNS was a component of first recurrence in 1.3% of patients (126 of 9524). In ten years the incidence were found to be 1% for her2 -and 2.7% for Her2+ disease (6) . That is why the patient population of this study is so rare.
We couldn't find significant effect of adjuvant chemo therapy, hormonal therapy or trastuzumab on survival after brain metastases. Also trastuzumab and platins in metastatic setting didn't effect the survival, patients who were administered lapatinib after they were diagnosed with brain metastases, live longer than the patients who weren't. This date is consistent with data of Cetin et al (9) . They showed that median pro gression free survival of patients who received lapatinib and and capecitabine was 7 months (95% confidence interval (CI) 5-9), with a median overall survival of 13 months (95% Cl 9-17). mOS in our date look longer than expected. It may be due to a patient who lived longer than normal and due to the limited number of patients evaluated in this subgroup.
In our study like the previous guiding studies surgery and WBRT has better survival out comes (mPFS 8.1 vs. 9.1 months and mOS 17.7 vs 13.6 months). But the results could not reach the statistical significance, probably due to the limited umber of patients. Altundag et al found that only age at diagnosis and ER status were associated significantly with overall survival in the multivariate analysis in patients with breast cancer brain metastases (10) . Although, ER, PR positivity are known to be good prognostic factors, it seems like they don't have signifi Brain metastases in breast cancer patients is an issue which have to be reevaluated in the era of modern treatment modalities, targeted therapies and prognostic factors. Unlike the classical approach to these pa tients, which suggests only evaluating and treating them when they become symptomatic, some subgroups may benefit from early and different treat ment modalities and also targeted therapies after me tastases may yield a better outcome. Some prognostic factor may help us to foresee which group may benefit more from which treatment modality. To clarify these issues, the need for studies with larger groups of patients is obvious.
